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INTRODUCTION
Management of patients with atypical squamous
cells of undetermined significance (ASC-US) and
atypical squamous cells cannot exclude high-grade
intraepithelial lesion (ASC-H) remains controver-
sial. The guidelines incorporate the Bethesda sys-
tem 2001 terminology and triage study: immediate
colposcopy, triage based on HPV DNA testing, and
repeat cytology at 6 to 12 months intervals. The
American College of Obstetricians andGynecolo-
gists has published recommendationsfor manage-
ment of abnormalcervical cytology findings.
Cervical cytology abnormalities lead to pre-
cancerous lesion by infection of human papil-
lomavirus (HPV) through sexual transmission. HPV
Infection of cervical epithelial, viral persistence,
progression and persistent infection likely reflect
to higher risk of cervical cancer. Cervical cancer
was the third most common cancer in women, es-
timated 530,000 new cases and 275,000 women
deaths due to cervical cancer worldwide in 2008.
About 85% cervical cancer cases occur in develop-
ing countries. Proper early detection and manage-
ment of precancerous lesion as an effort to preven-
tion and reduction number of cervical cancer.
Abstract
Objective: To review for the management of abnormal cervical cy-
tology: atypical squamous cells of undetermined significance (ASC-
US) and atypical squamous cells cannot exclude high-grade intraepi-
thelial lesion (ASC-H) as a treatment of cervical precancerous lesions
in order to avoidexcessive treatment, reduce of unnecessary exami-
nations and to provide cost effectively.
Method: Literature study on published literatures and studies about
the management of cervical cytology.
Conclusion: The results of ASC-US cervical cytology and ASC-H is
aninitial screening to detect precancerous cervical lesions. Definitive
therapy should be done when finding a low-grade lesions (LSIL) and
high degree of lesion(HSIL) squamous intraepithelial. A clinician ex-
pected to understand the natural history of HPV infection and the
management of precancerous cervical lesions properly.
[Indones J Obstet Gynecol 2013; 37-3: 166-170]
Keywords: ASC-H, ASC-US, cervical cytology abnormalities, cervical
precancerous lesion.
Abstrak
Tujuan: Sebagai telaah untuk mengevaluasi keputusan klinis dalam
tatalaksana hasil sitologi abnormal serviks:a typical squamous cells of
undetermined significance (ASC-US) dana typical squamous cells can
not exclude high-grade intraepithelial lesion (ASC-H) sebagai terapi
lesi prakanker serviks untuk menghindari tatalaksana berlebih, me-
ngurangi pemeriksaan yang tidak perlu dan memberikan biaya yang
lebih efektif.
Metode: Telaah pustaka dari berbagai literature dan penelitian me-
ngenai tata laksana hasil sitologi serviks.
Kesimpulan: Hasil dari sitologi serviks ASC-US dan ASC-H merupakan
suatu skrining awal dalam mendeteksi adanya lesi prakanker serviks.
Terapi definitif sebaiknya dilakukan bila ditemukan adanya lesi dera-
jat rendah (LSIL) dan lesi derajat tinggi (HSIL) intra epithelial sel
skuamosa. Seorang klinisi diharapkan memahami riwayat infeksi HPV
dan manajemen lesi prakanker serviks yang tepat.
[Maj Obstet Ginekol Indones 2013; 37-3: 166-170]
Kata kunci: ASC-H, ASC-US, lesi prakanker serviks, sitologi abnormal
serviks.
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Natural History of Human Papilloma Virus
Infection
Human Papilloma Virus (HPV) is DNA virus gener-
ally infect the mucosa or cutaneous epithelium. Vi-
rus entersthrough inflammation or trauma into the
basal cell layer and express their genes and begin
process to replication. Integration of HPV DNA dis-
rupts early (E1/E2) viral genes regulatory leading
to increased expression of E6 and E7, whereas
these genes have ability to inhibit tumor suppres-
sor genes (p53 and retinoblastoma gene/pRB) that
induce abnormalities of cell proliferation, histologic
features and cellular immortalization. Subse-
quently, Late viral genes (LI and L2) are expressed
to form structural protein that responsible to DNA
packaging and virionsassembly. Final differentia-
tion of epithelial cells produce new infectious
virions and release of infectious virus shed through
cell desquamation.1
Prevalence of Human Papilloma Virus In-
fection
Genital HPV infection is the most common sexual
transmitted disease among in women. Prevalence
of HPV infection ranges from 2-44%.2 The preva-
lence of abnormal cervical cytology relatively high
in adolescents, with rates of ASC-US ranging from
10%-13%, LSIL 3%-9% and HSIL 0.7% -3% The
prevalence of invasive cervical cancer is low in
women with ASC-US (approximately 0.1-0.2%).3
The peak prevalence of HPV infection in women
younger than 25 years with rate 20%-25% and
start falling in 30 years with rate around 10% (re-
mains stable into 60 years). A recent report in the
United States showed 40% of women aged 14 to
19 years were infected with HPV and 49.3% sexu-
ally active women aged 20 to 24 years had HPV
but prevalence dropped over 24 years of age.4
Studies in United States showed approximately
25% of older women were infected (27.8% of 25-
29 year olds, 27.3% of 30-39 year olds, 23.9% of
40-49 year olds and 20.2% of 50-59 year olds).5
Role Human Papilloma Virus Infection in
Cervical Cancer
Epidemiological studies show there is a strong as-
sociation between high risk HPV infection and cer-
vical cancer. More than 100 types of HPV have
been identified and 25 types infect the genital tract.
HPVs are classified as low risk and high risk types.
(wheeler. 2008) Infection of low risk HPV types
6,11 (6 and 11) can regress spontaneously but per-
sistent infection associated with development of be-
nign lesion of genital warts. Persistent infection of
high risk HPV(16,18,31,33,35,39,45,51,52,56,58,59,73
and 82) have greater risk of moderate or severe
cervical dysplasia which associated with develop-
ment of cervical cancer.6,7
HPV is a transient infection for most women, the
duration of most infections generally 7-10 months
(Ho GY. N Engl J Med.1998) and within 3 years of
observations 70-93% become undetectable or re-
gression. Women who show persistence infection
remain at risk for the development of cancers. Mul-
tiple factors influence the development of cancer
include behavioral (multiple partners, early age of
first sexual intercourse and immunosuppression
condition). Final mechanisms of development cer-
vical cancer are not well understood, suggest dis-
ruptions cell cycle and telomerase are the key fac-
tors and oncogenic properties of HPV because E6
and E7 enhance p53 degradation. E6 induce acti-
vates of telomerase (telomere lengthening enzyme)
leading to cellular immortalization and E7 also
block cells to apoptosis.
Cervical Cytologic of ASC-US
Thereare several classifications of cervical cytology
terminology such as Papaniculaou classification,
Reagan classification (a typical, milddy splasia,
moderate dysplasiaand severe dysplasia), Richart
classification (CIN1, CIN2 and CIN3), and the new
classification of the Bethesda System. The Bethesda
System was update in 2001 to clarify cervical cy-
tology results.8 The Bethesda System (TBS) is the
standard classification system used for reporting
Pap test results and to promote effective commu-
nication of cytology results from cytopathologist
and clinician. This system classifies as squamous
cell abnormalities suggestive of intraepithelial le-
sions (ASC-US and ASC-H), squamous intraepi-
thelial lesion (LSIL and HSIL) and squamous cell
carcinoma and the World Health Organization
(WHO) classifies as atypia, condyloma, cervical in-
traepithelial neoplasia (CIN1, CIN 2, CIN 3), carci-
noma in situ and squamous cell carcinoma.4
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There are several classifications of cervical cy-
tology terminology such as Papaniculaou classifica-
tion, Reagan classification (a typical, milddy splasia,
moderate dysplasia and severe dysplasia), Richart
classification (CIN1, CIN2 and CIN3), and the new
classification of the Bethesda System.
The cytopathologist act as a guide for the clini-
cian to have satisfactory management of ASC-US so
hope the cytopathologist and clinician must com-
municate clearly and frequently to any suspicious
regarding the changes occurring in the cervix when
a smear has reported as ASC-US.9 ASC used to de-
scribe cellular abnormalities that suggestive of SIL
but are not able to definitively diagnosed as SIL.
ASC-US is considered to benign lesions, cytology
criteria of ASC-US include loss of normal nu-
clear/cytoplasm ratio due to nuclear enlargement
and nuclear hyperchromatic. Atypical squamous
cells cannot exclude HSIL (ASC-H) is associated
with an increasing predictive value for detecting a
more serious lesion.The diagnosis of ASC-H on Pap
smear is associated with an appreciable risk of
clinically significant disease. Patients with an ASC-
H Pap smear result should undergo timely
colposcopic and histologic assessment to rule out
HSIL, and cervical cancer.10
HPV Testing as an Adjunct to Cervical Cy-
tology
Cervical cytology screening has been successful in
reducing rates of cervical cancer, but there are
limitations to the use cytology which characterized
by errors in sampling, slide preparation, classifica-
tion of results, interpretation and categorizes cy-
tology results. HPV as adjunct to cytology has ap-
proved by FDA, use of HPV testing as triage stra-
tegy is highly sensitive, specific, effective and
potentially economical as an adjunct to ASC-US cy-
tology as primary screening and detectionfor se-
vere dysplasia.11 Cytology and HPV testing have a
sensitivity and specificity of 91%, National Cancer
Institute, ASCCP and the American Cancer Society
concluded that the use of adjunctive HPV testing
for women over 30 years was an acceptable strat-
egy.12  HPV testing in women with ASCUS has a
negative predictive value of 99.5%, meaning that if
an HPV test has a negative result, it is highly un-
likely that disease is present.13
Rates of HPV DNA positivity are much higher in
younger compared with older women with ASC-
US.14,15 Using HPV testing to manage adolescent
with ASC-US would refer women at risk to col-
poscopy. Conservative follow-up with repeat cy-
tology and HPV testing at 12 months appears to be
the best management approach for cytology nega-
tive and HPV positive women. Women who on re-
peat testing are persistently HPV positive should
undergo colposcopy, whereas women negative on
both tests can be rescreened in 3 years.16
Management of women with ASC-US
Three major management strategies have been
used inthe United States for management of
women with ASCUS cervical cytology: immediate
colposcopy, triage based on HPV DNA testing, and
repeat cytology at 4- to 6-month intervals.17 Ma-
nagement guidelines for women with abnormal cy-
tology results based on the 2001 Bethesda system
which sponsored by American Society for Col-
poscopy and Cervical Pathology (ASCCP), collabo-
rate and integrated terminology and management
guidelines provide more effective of women with
cervical abnormalities.8 Management guidelines
recognized 3 management strategies for women
Table 1. Classifications of cervical cytology terminology
Papaniculaou Class 1 Class 2 Class 3 Class 4 Class 5
Reagan Normal Inflammation/
Inconclusive
Mild
Dysplasia
Moderate
Dysplasia
Severe
Dysplasia
CIS Cancer
Richart Normal Atypia CIN 1 CIN II CIN III CIN III Cancer
Bethesda 1991 Normal Benign
Cellular
Changes
ASCUS LGSIL HGSIL HGSIL HGSIL Cancer
Bethesda 2001 Normal ASC-US/ASC-H LGSIL HGSIL HGSIL HGSIL Cancer
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with ASC-US according to a large, prospective, mul-
ticenter and randomized trial by National Cancer
Institute.15,16
Clinical data have demonstrated that 2 repeat
cytology examinations performed at 6 months in-
terval, testing for HPV and colposcopy examination
are all safe and effective apptoaches to managing
women with ASC-US.17 HPV triage does not effi-
cient in young patient with ASC-US.4
Management of ASC-US in women 20 years and
older include three acceptable follow up ap-
proaches, including monitoring every 6 months for
a year, referral to immediate colposcopy and test-
ing for HPV DNA. Adolescents women 20 years and
younger are considered separately from women 21
and older in guidelines for the management abnor-
mal cytology. In adolescents, ASC-US or LSIL de-
tected by screening should be monitored with re-
peated cytology every 12 month, if at the first 12
month follow up (HSIL or ASC-H) is detected, pa-
tient should be referred to colposcopy for biopsy.
If at the first 12 month follow up (normal, or LSIL
or ASCUS) is detected, patient continue monitored.
Routine screening should resume if cytology nor-
mal at the second 12 month follow up (at 24
months). If at 24 months cytology shows LSIL, AS-
CUS, ASC-H or HSIL, patient should be referred to
colposcopy.18
ASC-US in immunosuppressed, postmeno-
pausal women and pregnancy
All immunosuppressed, postmenopausal women
and HIV women with ASC-US undergo colposcopy,
and should be managed in the same manner as
women in the general population regardless of
anti-retroviral therapy.12,16 Management options
for pregnant women over 20 years old with ASC-US
are same as nonpregnant women, with the excep-
tion that it is acceptable to defer colposcopy until
at least 6 weeks postpartum.16
Management of women with ASC-H
Regardless of age, Women with ASC-H should
prompt a referral to colposcopy, If high grade le-
sion not identified follow up with cytology testing
at 6 and 12 months or HPV DNA test at 12 months
is acceptable. Referral to colposcopy is recom-
mended for women with positive HPV DNA or have
ASC-US or greater on their repeat cytologic tests.
If the HPV DNA test is negative or if 2 consecutive
repeat cytologic tests are negative for intraepi-
thelial lesion or malignancy, routine cytologic
screening is recommended.If Colposcopy evalu-
ation identified high grade lesion (CIN 2 and 3 by
histopathology), manage per ASCCP guideline is
recommended.4,16
CONCLUSION
Cervical cytology results of ASC-US and ASC-H are
a terminology in screening cells, where the cells
could not be categorized as low-grade (CIN1, mild
dysplasia), or normal. ASC-US andASC-H could only
be used as a screening and not a diagnostic modal-
ity. Definitive therapy should only be made based
on the results of histopathology and further exami-
nation. Appropriate treatment help physicians to
prevent excessive therapy and inadequate therapy.
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